Pathology activated prodrugs targeting Nrf2 to treat neuropathic pain

The antioxidant nuclear factor erythroid 2-related factor 2 (Nrf2) is a desirable therapeutic target for a broad range of pathologies, including chronic pain. However, current Nrf2 activators are limited by unwanted effects due to non-specificity, and systemic distribution and action. We aimed to overcome these long-standing issues by creating a compound that would mask the unwanted electrophilic nature of the Nrf2 activator monomethyl fumarate (MMF) until selective generation of MMF at sites of oxidative pathology associated with pain.

Source: The Journal of Pain - May 1, 2022 Category: Materials Science Authors: Jiahe Li, Thomas D. Avery, Dion J.L Turner, Fisher R. Cherry, Mohd S. Ur Rasheed, Clarissa Aguilar, Andrew J. Shepherd, Jingxian Yu, Andrew D. Abell, Peter M. Grace Tags: 5 Source Type: research